Two highly regulated sectors, two different public positions. The useful question is not who is "better". It is whether decades of lifecycle evidence practice make consequential AI easier to evidence, challenge and keep under control when scrutiny arrives.
Two highly regulated sectors. Two different public positions.
Both healthcare and finance are sophisticated, highly regulated environments. Both have mature risk functions and high consequences when automation goes wrong. Yet the first RATE AI release places healthcare at BB and finance and credit at CC.
The comparison should be read as an evidence-supported public position, not a universal verdict on safety or governance quality. Still, the contrast becomes more interesting when placed beside the wider regulatory environment.
Healthcare has decades of evidence muscle memory
The U.S. FDA reported more than 1,300 authorised AI-enabled medical devices by the end of 2025. Its public device list is explicitly designed to improve transparency and links to releasable safety and effectiveness information. FDA guidance also treats AI-enabled devices through a total-product-lifecycle lens, connecting design, maintenance, documentation and post-market change.
That does not prove why healthcare receives a stronger RATE AI band. It does suggest a plausible institutional pattern: sectors that have long been required to generate structured evidence before and after market entry may possess stronger assurance muscle memory when AI arrives.
Finance is scaling AI at extraordinary speed
The EBA observed in September 2025 that 92% of EU banks were already deploying AI. The Financial Stability Board, looking at the same broad trend, called on authorities to address information gaps, test whether existing frameworks remain adequate and strengthen supervisory capabilities.
This makes the RATE AI CC position strategically important. The message is not that financial institutions lack governance. It is that the assurance problem grows with the estate: many use cases, multiple models, third-party dependencies, rapidly changing general-purpose AI, customer-facing decisions and overlapping prudential, conduct, privacy and AI rules.
In that environment, a mature control function can still struggle to answer one deceptively simple question: can the organisation demonstrate the chain from model behaviour to business decision to human accountability across the whole portfolio?
The competitive issue is the distance between control and proof
For regulated industries, the next advantage may come from shortening that distance. If two organisations have similar technical capability, the one that can produce a cleaner decision trail, faster cross-jurisdiction mapping and clearer ownership may be easier to approve, procure, insure, supervise or integrate after an acquisition.
What a board should look for
Where are the systems whose operational importance has grown faster than their assurance record?
Which supplier or model dependencies make it hard to explain the decision chain?
Which controls exist but cannot yet be independently verified?
Which systems would be expensive to pause because the organisation has become dependent on them?
What RATE AI is watching next
Whether healthcare retains its lead as the sample expands.
Whether finance closes the public assurance gap as AI governance moves from pilots to portfolio infrastructure.
Whether lifecycle evidence practices predict stronger bands across other regulated industries.
Official context: FDA AI-enabled medical device list · FDA total-product-lifecycle guidance · WHO/Europe AI health readiness · EBA, AI in EU banking · FSB, AI and financial stability.
Reading note: RATE AI ratings are independent risk-intelligence positions, not legal opinions or certificates of regulatory compliance. Technical methodology remains in the Public White Paper v1.1.